You are here
Welcome & Introduction" by Nicholas ThatcherNicholas Thatcher introduces the symposium topic: “Debating the optimal management in advanced and metastatic lung cancer: The right treatment for the right patient at the right time”.
'Identifying the right patient: histological and molecular profiling challenges' by Keith KerrWith more insights into the molecular characteristics of lung cancer cells and the evolvement of new technologies diagnosis and treatment is more targeted and equally complicated – a lecture of Keith Kerr, University of Aberdeen.
"Maximizing Treatment Outcomes in Patients with Advanced Metastatic Lung Cancer" by Giorgio V ScagliottiGiorgio Scagliotti builds a modern-day algorithm for selecting individualized therapies in nonsquamous non-small cell lung cancer and squamous non-small cell lung cancer based on molecular biomarkers and clinical trial results. He highlights the improvements in our abilities to better target therapies but also addresses the limitations in translating clinical trial data to the clinical setting, and discusses the gaps in therapy that still remain in this patient population. Finally, he comments on the issues remaining with effectively incorporating immunotherapy strategies into the clinic.
"The right time, the right sequence" by Nicholas ThatcherUsing a case study in a 76-year old male with squamous non-small cell lung cancer, Dr Thatcher explores the significance of clinical trial results from a clinician’s perspective versus those of a patient. He suggests that while a 6-week increase in overall survival may be considered to be a minimal improvement by clinicians, to the patient it could mean a great deal. He also challenges the guidelines that currently define the age that is “too old” for chemotherapy, citing evidence that in people over 70 years of age chemotherapy can have substantial benefits.
"Medical management of advanced NSCLC" by Christian ManegoldThree antiangiogenic agents have been incorporated into current treatment algorithms for non-small cell lung cancer (NSCLC). Dr Manegold reviews clinical trial data that supports the addition of these agents to platinum-based chemotherapy, as well as the addition to other targeted agents such as monoclonal antibodies or small tyrosine kinase inhibitors. He discusses early results from small clinical trials that combine antiangiogenic agents with immune-checkpoint inhibitors. He also explores the questions that remain for creating a treatment algorithm for combining antiangiogenic agents with immune-checkpoint inhibitors for NSCLC therapy.